ArticleScientific reports2026
PSMC2 serves as a potential regulatory target of EZH2 in promoting glioma progression via epithelial-mesenchymal transition.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Enhancer of Zeste Homolog 2 (EZH2): From Glioblastoma Biology to Potential Epigenetic Therapy.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Proteasome 26 S Subunit, ATPase 2 (PSMC2) was initially thought to be associated with the removal of misfolded or damaged proteins and the removal of excess proteins that are no longer necessary. However, recent studies have found that PSMC2 acts as an oncogene in the human body. In our research, PSMC2 serves as a tumor-initiating factor in glioma. Bioinformatics analysis of public databases, along with an examination of PSMC2 expression in glioma patients, revealed its high expression at both the mRNA and protein levels in this type of tumor. The expression of PSMC2 exhibits a negative correlation with glioma patient prognosis. Modulating PSMC2 levels through inhibition or overexpression alters glioma cell morphology and suppresses both proliferation and motility. Silencing PSMC2 impedes epithelial-mesenchymal transition (EMT), concurrently altering cellular polarity and cytoskeletal architecture. Mechanistically, proteomics analysis, corroborated by co-immunoprecipitation (CO-IP) and fluorescence co-localization assays, identified a interaction between PSMC2 and Enhancer of Zeste Homolog 2 (EZH2). Our research findings indicate that PSMC2 can promote the occurrence and development of glioma, and this process is closely related to EZH2. Targeting the PSMC2-EZH2 axis may become a promising option for glioma treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.